Skip to main content
Contact Info
Tatyana Doktorova
Senior Toxicologist at Edelweiss Connect

Dr Tatyana Doktorova is a Senior Toxicologist and Head of Safety Assessment Laboratory at Edelweiss Connect. She is a European Registered Toxicologist with a PhD in Pharmaceutical Sciences and also a Marie Curie Individual Fellowship recipient.

Dr Doktorova has strong knowledge in the field of omics-based technologies, biomarker and pathway discovery of mutagen- and non-mutagen-induced hepatocellular carcinoma. Furthermore, she has extensive background in liver-based in vitro models, in vitro mutagenicity/genotoxicity assays, reporter-based assays, alternative methods for hazard identification. Her most recent projects are focused on the development of an automated workflows for AOP hypothesis generation.

Her research efforts have resulted in authorship, co-authorship or senior authorship of more than 20 peer-reviewed scientific publications.

OpenTox Euro 2019 worksop: The Use of Adverse Outcome Pathways in Safety Assessment

In view of the global legislative changes, which aim to increase the speed of evaluation of chemicals, reinforce the use of alternative methods, and at the same time remain reliable in their ability to identify the chemicals of potential concern, a better understanding of the mechanisms leading to the development of a specific disease is needed. The Adverse Outcome Pathway (AOP) is a toxicological construct that links a molecular initiating event to the adverse outcome via key events, in a way specified by key event relationships. The potential of the AOP concept is being currently recognized by regulators with the biggest advances so far mostly in the field of skin sensitization. By a carefully selected combination of tests targeting the outlines KEs involved in skin sensitization, it has been shown that the concordance with human data (90%) is even higher than the traditionally used LLNA (82%). The global goal in the AOP field is to reach this level of maturity and applicability for more endpoints. This is hindered, however, by the slow, time-consuming process of AOP development. Recent efforts have been initiated to accelerate the assembly of these series of “biological dominos” by the use of computational approaches for association rule mining. In a case study we show the applicability of these approaches and outline their potential.

OpenTox Euro 2019 session 5 overview: AOPs current trends and developments as exemplified by case studies

The Adverse Outcome Pathway is a framework which describes the initial interaction of a stressor with a biomolecule and continuing with dependent series of intermediate key events (KEs) at different levels of biological organization, while finally ending in an adverse outcome (AOP). The primary objective for the introduction of the AOP concept was knowledge assembly, specifically, making information attained through scientific research by subject-matter experts and distributed in the body of scientific literature accessible to regulators during the decision-making process. It was then quickly recognized as a tool to enhance communication between scientists involved in generating biological/toxicological data and the potential end users of this information, such as modelers or risk assessors. In this session, we would like to provide an update of the current advances of scientists in the area as exemplified by case studies.